BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 27474328)

  • 21. Gadoxetic acid-enhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteria.
    Rhee H; Kim MJ; Park YN; Choi JS; Kim KS
    J Magn Reson Imaging; 2012 Feb; 35(2):393-8. PubMed ID: 21990116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
    Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
    Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI.
    Jeon SK; Joo I; Bae JS; Park SJ; Lee JM
    Eur Radiol; 2022 Jan; 32(1):46-55. PubMed ID: 34132875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
    Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM
    Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?
    Joo I; Lee JM; Lee DH; Jeon JH; Han JK
    Eur Radiol; 2019 Apr; 29(4):1724-1732. PubMed ID: 30255250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of gadoxetic acid-enhanced and diffusion-weighted MR imaging in evaluation of hepatocellular carcinomas with atypical enhancement pattern on contrast-enhanced multiphasic MDCT in patients with chronic liver disease.
    Kim HS; Kim SH; Kang TW; Song KD; Choi D; Park CK
    Eur J Radiol; 2015 Apr; 84(4):555-62. PubMed ID: 25617950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
    Kim YY; An C; Kim S; Kim MJ
    Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI.
    Ko A; Park HJ; Lee ES; Park SB; Kim YK; Choi SY; Ahn S
    Clin Radiol; 2020 Apr; 75(4):319.e1-319.e9. PubMed ID: 31858990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Added value of enhanced CT on LR-3 and LR-4 observation of Gd-EOB-DTPA MRI for the diagnosis of HCC: are CT and MR washout features interchangeable?
    Lim K; Kwon H; Cho J; Kim D; Kang E; Kim S
    Br J Radiol; 2022 Apr; 95(1132):20210738. PubMed ID: 34928175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LI-RADS v2017 categorisation of HCC using CT: Does moderate to severe fatty liver affect accuracy?
    Kim SS; Hwang JA; Shin HC; Choi SY; Kang TW; Jou SS; Lee WH; Park S; Heo NH
    Eur Radiol; 2019 Jan; 29(1):186-194. PubMed ID: 30073499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Contrast-Enhanced Ultrasound versus Contrast-Enhanced Magnetic Resonance Imaging for the Diagnosis of Focal Liver Lesions Using the Liver Imaging Reporting and Data System.
    Wang JY; Feng SY; Yi AJ; Zhu D; Xu JW; Li J; Cui XW; Dietrich CF
    Ultrasound Med Biol; 2020 May; 46(5):1216-1223. PubMed ID: 32115307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.
    Horvat N; Nikolovski I; Long N; Gerst S; Zheng J; Pak LM; Simpson A; Zheng J; Capanu M; Jarnagin WR; Mannelli L; Do RKG
    Abdom Radiol (NY); 2018 Jan; 43(1):169-178. PubMed ID: 28765978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid-enhanced liver MRI.
    Kang HJ; Lee JM; Jeon SK; Jang S; Park S; Joo I; Yoon JH; Han JK
    Eur Radiol; 2021 Feb; 31(2):824-833. PubMed ID: 32845387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT.
    Inoue T; Kudo M; Komuta M; Hayaishi S; Ueda T; Takita M; Kitai S; Hatanaka K; Yada N; Hagiwara S; Chung H; Sakurai T; Ueshima K; Sakamoto M; Maenishi O; Hyodo T; Okada M; Kumano S; Murakami T
    J Gastroenterol; 2012 Sep; 47(9):1036-47. PubMed ID: 22526270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation.
    Odedra D; Jandaghi AB; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G; Jhaveri KS
    Cancer Imaging; 2022 Oct; 22(1):55. PubMed ID: 36195953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
    De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma.
    Yoo SH; Choi JY; Jang JW; Bae SH; Yoon SK; Kim DG; Yoo YK; Rha SE; Lee YJ; Jung ES
    Ann Surg Oncol; 2013 Sep; 20(9):2893-900. PubMed ID: 23649931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simplified LI-RADS for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI.
    Kwag M; Choi SH; Choi SJ; Byun JH; Won HJ; Shin YM
    Radiology; 2022 Dec; 305(3):614-622. PubMed ID: 35972362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in recipients of living-related-liver-transplantation: comparison with dynamic multidetector row computed tomography and angiography-assisted computed tomography.
    Kakihara D; Nishie A; Harada N; Shirabe K; Tajima T; Asayama Y; Ishigami K; Nakayama T; Takayama Y; Okamoto D; Fujita N; Kishimoto J; Honda H
    J Magn Reson Imaging; 2014 Nov; 40(5):1112-20. PubMed ID: 24259437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.